Abbott Laboratories (NYSE:ABT) Shares Acquired by Chatham Capital Group Inc.

Chatham Capital Group Inc. increased its position in shares of Abbott Laboratories (NYSE:ABT) by 21.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,563 shares of the healthcare product maker’s stock after buying an additional 2,045 shares during the period. Chatham Capital Group Inc.’s holdings in Abbott Laboratories were worth $1,534,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Redwood Park Advisors LLC purchased a new position in Abbott Laboratories in the fourth quarter valued at about $25,000. Noble Wealth Management PBC bought a new stake in Abbott Laboratories during the fourth quarter worth approximately $26,000. NewSquare Capital LLC grew its position in Abbott Laboratories by 78.4% in the fourth quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock worth $27,000 after buying an additional 105 shares during the last quarter. WealthTrak Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at $28,000. Finally, Rialto Wealth Management LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter worth $29,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 0.5%

Shares of Abbott Laboratories stock opened at $132.99 on Thursday. The business has a fifty day simple moving average of $130.69 and a two-hundred day simple moving average of $125.54. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The company has a market capitalization of $231.38 billion, a price-to-earnings ratio of 17.38, a P/E/G ratio of 2.52 and a beta of 0.74. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. Research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Analyst Ratings Changes

ABT has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Bank of America increased their price objective on Abbott Laboratories from $133.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Raymond James boosted their price target on Abbott Laboratories from $132.00 to $142.00 and gave the stock an “outperform” rating in a research report on Thursday, April 17th. Stifel Nicolaus raised their price objective on shares of Abbott Laboratories from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, April 17th. Finally, Barclays lifted their price objective on Abbott Laboratories from $158.00 to $159.00 and gave the company an “overweight” rating in a research report on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $142.59.

Insiders Place Their Bets

In related news, Director Sally E. Blount sold 2,600 shares of the firm’s stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the transaction, the director now owns 34,058 shares in the company, valued at approximately $4,415,960.28. This trade represents a 7.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.